Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,040,013
  • Shares Outstanding, K 179,926
  • Annual Sales, $ 1,704 M
  • Annual Income, $ -23,850 K
  • 60-Month Beta 1.04
  • Price/Sales 8.92
  • Price/Cash Flow 132.62
  • Price/Book 4.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.12
  • Number of Estimates 8
  • High Estimate 0.21
  • Low Estimate 0.07
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +220.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.25 +26.10%
on 03/23/20
97.10 -11.37%
on 03/05/20
-8.34 (-8.83%)
since 03/02/20
3-Month
68.25 +26.10%
on 03/23/20
97.10 -11.37%
on 03/05/20
+2.02 (+2.40%)
since 01/02/20
52-Week
62.88 +36.86%
on 10/02/19
97.10 -11.37%
on 03/05/20
-5.17 (-5.67%)
since 04/02/19

Most Recent Stories

More News
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BMRN : 86.06 (+2.95%)
Biomarin Pharmac Set to Possibly Pullback After Yesterday's Rally of 8.20%

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $74.34 to a high of $78.22. Yesterday, the shares gained 8.2%, which took the trading range above the 3-day high...

BMRN : 86.06 (+2.95%)
5% Surge Recovers More Than Half of Yesterday's Plunge

5% Surge Recovers More Than Half of Yesterday's Plunge

UNG : 11.75 (-2.16%)
UGAZ : 20.46 (-6.36%)
STMP : 124.18 (-0.07%)
KR : 31.60 (+3.61%)
ADP : 131.55 (+1.41%)
OXY : 12.77 (+18.90%)
WYNN : 52.67 (-2.46%)
IR : 23.04 (-3.15%)
WWE : 34.65 (+3.13%)
BMRN : 86.06 (+2.95%)
MIME : 32.38 (-3.00%)
SPR : 18.73 (-4.49%)
TTD : 164.78 (-4.36%)
AYX : 83.50 (-5.71%)
TQQQ : 44.20 (+5.92%)
BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan, M.D., Ph.D., has been named to the San Francisco Business Times 2020 "40 Under 40" list. Now in its ninth year, the...

BMRN : 86.06 (+2.95%)
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus

BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.

REGN : 498.75 (+0.42%)
SNY : 43.51 (+1.40%)
BMRN : 86.06 (+2.95%)
VRTX : 242.16 (+7.40%)
Stock Market News for Feb 27, 2020

U.S. equities disappointed on Wednesday, as most of the major benchmarks ended mostly lower.

BMRN : 86.06 (+2.95%)
ETSY : 34.80 (-1.83%)
NVEE : 40.00 (+4.41%)
BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BMRN : 86.06 (+2.95%)
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

https://mma.prnewswire.com/media/534018/BioMarin_Pharmaceutical_Inc_Logo.jpg

BMRN : 86.06 (+2.95%)
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?

Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.

SNY : 43.51 (+1.40%)
BMRN : 86.06 (+2.95%)
AMAG : 6.08 (-1.62%)
VCEL : 8.62 (+1.29%)
BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%

BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

BMRN : 86.06 (+2.95%)
GH : 65.12 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BMRN with:

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

2nd Resistance Point 88.79
1st Resistance Point 87.42
Last Price 86.06
1st Support Level 83.40
2nd Support Level 80.75

See More

52-Week High 97.10
Last Price 86.06
Fibonacci 61.8% 84.03
Fibonacci 50% 79.99
Fibonacci 38.2% 75.95
52-Week Low 62.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar